Praxis Precision Medicines, Inc.

PRAX Healthcare Biotechnology

Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023. In the quarter to June 2026, revenue grew 1,349.1%, EPS grew 13.3% and free cash flow fell 43.5%, each against the same quarter a year earlier.

241.76 6.48 −2.61%
Market cap
$6.9B
P/E
0.0×
Fwd P/E
−24.3×
Dividend yield
—
F-score
n/a
Altman Z
19.09
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
15.73 15.88 10.22 5.18
Net Debt/EBITDA
7.78 7.39 6.14 3.38
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(2.70) (2.98) (3.39) (2.96)
Book value per Share
46.03 48.81 39.02 15.63
Free Cash Flow
(78.56) (86.21) (76.32) (65.06)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates